Arhivi

Moč partnerstva. Švica in Kitajska sta zgled.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Življenja, primerna za življenje - nova knjiga, ki predstavlja zgodbe ljudi, ki jih je prizadela HD po vsem svetu.

TISKOVNO POROČILO - 25. oktober 2024, Moskva, Idaho, ZDAZ veseljem napovedujemo izid nove knjige o Huntingtonovi bolezni (HD) z naslovom Življenjska življenja: Življenjsko življenje: Pogovori s Huntingtonovo boleznijo, [...]

Družba LoQus23 Therapeutics je napovedala financiranje v višini 35 milijonov funtov za razvoj novega zdravila za zaviranje somatske širitve pri Huntingtonovi bolezni

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

MENA kongres za redke bolezni

Kongres HDYO

FDA podeli hitri postopek za program PTC518 za Huntingtonovo bolezen

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

Pridopidin družbe Prilenia za Huntingtonovo bolezen sprejet za pregled evropskega dovoljenja za promet

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

Kronika neusmiljenega iskanja: Oblikovanje fundacije

Pripadam tretji generaciji družine, ki jo je prizadela Huntingtonova bolezen, vendar je šele leta 2024 zaradi neutrudnih prizadevanj mojega drugega očeta F. Cooka [...]

IROS, Prilenia in Mednarodno združenje za Huntingtonovo bolezen sodelujejo pri prvem preskušanju Huntingtonove bolezni v regiji MENA

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International […]

uniQure objavlja pozitivne vmesne podatke, ki dokazujejo upočasnitev napredovanja bolezni v I/II fazi preskušanja AMT-130 za HD

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” […]